A Prospective Clinical Study on the Neuroprotective Evaluation of Angiotensin Type 1 (AT1) Receptor Blockers Combined with an Excitatory Amino Acid Transporter-2 (EAAT-2) Activator in Patients with Cerebral Ischemia: A Review Article

Cerebral ischemia remains a major cause of mortality and long-term disability despite advances in reperfusion
therapy, because a substantial proportion of patients continue to experience progressive neuronal injury driven
by excitotoxicity, oxidative stress, microvascular dysfunction, blood–brain barrier disruption, and
neuroinflammation [1][2][3]. Angiotensin II type 1 receptor signaling contributes to ischemic injury through
vasoconstriction, inflammatory amplification, matrix metalloproteinase activation, edema formation, and
endothelial dysfunction, whereas pharmacologic AT1 receptor blockade has shown neuroprotective effects in
experimental stroke models that include reduced infarct volume, reduced edema, improved neurologic scores,
and partial preservation of cerebral blood flow [4][5][6][7]. In parallel, the astrocytic glutamate transporter
EAAT-2 is a central determinant of extracellular glutamate clearance, and reduced transporter activity during
ischemia is associated with excitotoxic neuronal death; strategies that increase EAAT-2 expression or
function, including ceftriaxone and experimental EAAT-2-enhancing approaches, have demonstrated
neuroprotective potential in preclinical models [8][9][2][10].
The therapeutic concept of combining an AT1 receptor blocker with an EAAT-2 activator is biologically
attractive because it targets two complementary arms of ischemic injury: angiotensin-driven neurovascular
inflammation and glutamate-mediated excitotoxicity [11][12][3]. Available evidence suggests that AT1
receptor blockade may reduce inflammatory conditions that impair glutamate transporters, while EAAT-2
activation may directly limit glutamate accumulation in the ischemic penumbra, thereby extending the
viability of salvageable tissue [11][5][2]. However, direct clinical evidence for the combination in patients
with cerebral ischemia is lacking, and no established randomized clinical pathway currently supports routine
use specifically for this purpose [13].
This review synthesizes mechanistic, preclinical, and translational evidence relevant to a prospective clinical
evaluation of AT1 receptor blockers combined with an EAAT-2 activator in cerebral ischemia. It proposes a
clinically relevant review framework covering pathophysiology, pharmacologic rationale, candidate agents,
safety considerations, endpoints, and manuscript-ready discussion points for publication. The cumulative
evidence supports the combination as a promising hypothesis-generating neuroprotective strategy that merits
carefully designed prospective clinical testing rather than immediate therapeutic adoption [11][12][13]